Clinical Trials Logo
  1. Home
  2. Renal Transplant
  3. NCT05632523
  4. Details
NCT05632523 Clinical Trial

Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients

Renal Transplant Clinical Trial

— EPIMAC-BELA  

Official title:
Surveillance Pharmacologique et Immunitaire précoce après Conversion au Belatacept Chez Les Patients Ayant Subi Une Transplantation rénale : étude Pilote

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05632523
Other study ID # DR210053
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 13, 2023
Est. completion date December 2024

Study information
Verified date June 2024
Source University Hospital, Tours
Contact Philippe GATAULT
Phone 02 47 47 37 46
Email philippe.gatault@univ-tours.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Single-center, prospective, translational, clinical-biological, multidisciplinary study

Description:

All patients starting belatacept will be informed about non-interventional study and will be included unless they do not accept (non-opposition, consent is not required). Patients will be included and followed up during the 6 first months, i.e. 9 infusions. Blood samples (3 heparinized tubes of 7ml + 1 dry tube without separator gel of 5ml, i.e. 26ml maximum per sample) and urine samples will be harvested before each perfusions and in case of rejection. Clinical and biological data will be collected in an electronic CRF.

Recruitment information / eligibility
Status Recruiting
Enrollment 15
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Renal transplant patient - Patient converted from an anticalcineurin to belatacept Exclusion Criteria: - Opposition to data processing - Hemoglobin < 9g/dL - Patient under judicial protection - Pregnant or breastfeeding woman

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Blood sample
Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
• urinary sample
Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion

Locations
Country Name City State
France University hospital Tours

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 0
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 14
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 28
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 42
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 2
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 3
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 4
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 5
Primary Lymphocyte subpopulations in blood before freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 6
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 0
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 14
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 28
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 42
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 2
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 3
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 4
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 5
Primary Lymphocyte subpopulations in blood after freezing Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 6
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 0
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 14
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 28
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 42
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 2
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 3
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 4
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 5
Primary Lymphocyte subpopulations in urine before freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 6
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 0
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 14
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 28
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Day 42
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 2
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 3
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 4
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 5
Primary Lymphocyte subpopulations in urine after freezing. Variability in absolute counts and relative proportions immunological analyses in flow cytometry Month 6
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Day 0
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Day 14
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Day 28
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Day 42
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Month 2
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Month 3
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Month 4
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Month 5
Secondary residual concentrations of belatacept pharmacological analyses by mass spectrometry Month 6
See also
  Status Clinical Trial Phase
Completed NCT01220050 - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism Phase 2
Completed NCT00820469 - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Phase 4
Completed NCT00239005 - Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation Phase 4
Completed NCT00270153 - The Use of ACE Inhibitors in the Early Renal Post-transplant Period Phase 1
Completed NCT02711826 - Treg Therapy in Subclinical Inflammation in Kidney Transplantation Phase 1/Phase 2
Completed NCT03837522 - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT01256294 - Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients Phase 4
Suspended NCT01059292 - TIPE2 Associated With Kidney Transplant N/A
Completed NCT00547040 - Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
Suspended NCT03043339 - Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt
Completed NCT02581644 - Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries N/A
Completed NCT01728012 - Long-term Cardiovascular Risk Following Successful Renal Transplantation N/A
Terminated NCT01011114 - Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant N/A
Completed NCT02117596 - Calcineurin Inhibitor Based Immunosuppression Withdrawal N/A
Completed NCT00555373 - Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression N/A
Recruiting NCT05156086 - Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
Completed NCT01334333 - Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients Phase 4
Recruiting NCT03107858 - The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function Phase 2/Phase 3
Completed NCT00352547 - Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation N/A